California, US-based MyoKardia has appointed Dr June Lee as chief operating officer and Dr Radhika Tripuraneni as vice president of medical affairs.
Dr Lee (pictured right) joins the cardiology specialist from the University of California, San Francisco (UCSF), where she was director of the therapeutics and digital health technologies accelerator programme, Catalyst, at the Clinical and Translational Science Institute and a professor at the UCSF School of Medicine.
Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech.
Meanwhile, Dr Tripuraneni (pictured left) brings over 10 years of medical affairs expertise in a variety of therapeutic areas – including rare and cardiovascular diseases – to MyoKardia.
Most recently, she served as vice president for medical affairs at Alexion Pharmaceuticals, and was cardiovascular medical director at Gilead Sciences before this. She also brings experience as global medical director and global medical affairs lead for two therapeutic areas at Genzyme.
Tassos Gianakakos, MyoKardia’s chief executive officer, said: “I am thrilled to welcome these two exceptional life sciences leaders to the MyoKardia team at this pivotal time as we expand our pipeline and advance new clinical candidates.
“Their expertise and counsel will broaden our base of leadership and support our mission to change the world for patients with serious cardiovascular disease.”